Marine- and plant-derived ω-3 fatty acids differentially regulate prostate cancer cell proliferation

Eser,Pinar  O.; Vanden Heuvel,John  P.; Araujo,John; Thompson,Jerry  T.

doi:10.3892/mco.2013.76

Marine- and plant-derived ω-3 fatty acids differentially regulate prostate cancer cell proliferation

Authors:
- Pinar O. Eser
- John P. Vanden Heuvel
- John Araujo
- Jerry T. Thompson
View Affiliations

Affiliations: Department of Veterinary Science and Center of Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, PA 16802, USA, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Published online on: February 15, 2013 https://doi.org/10.3892/mco.2013.76
Pages: 444-452

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fish oil contains the marine ω-3 polyunsaturated fatty acids (ω-3 PUFAs) docosahexaenoic (DHA) and eicosapentaenoic acid (EPA). The consumption of diets rich in these fatty acids is associated with a decreased incidence of prostate cancer. However, there is limited knowledge regarding the non‑marine ω-3 PUFA α‑linolenic acid (ALA). To study which ω-3 PUFAs are more effective in prostate cancer prevention, and whether the mechanisms of action are conserved between them, we investigated the effect of DHA, EPA and ALA on the human prostate cancer cell lines PC-3 and LNCaP. Different trends of inhibition of PC-3 cell proliferation were observed for the three ω-3 PUFA, with DHA having the most pronounced effects on cell proliferation, while ALA had the minimum effects of the three ω-3 PUFAs. All the ω-3 PUFAs decreased fatty acid synthase (FASN) mRNA. Concerning genes involved in inflammation, cell cycle and apoptosis, DHA regulated the most genes in all categories, followed by EPA and then ALA. In addition, DHA and EPA increased the gene expression of the pro-apoptotic protein activating transcription factor 3 mRNA. Moreover, these two fatty acids significantly induced apoptosis. In conclusion, while some mechanisms of cancer cell inhibition are conserved among ω-3 PUFA, the extent, magnitude, and duration of transcriptional changes vary for each individual fatty acid.

View Figures

View References

1.	Rambeaud JJ: Intermittent complete androgen blockade in meta-static prostate cancer. Eur Urol. 35(Suppl 1): 32–36. 1999. View Article : Google Scholar : PubMed/NCBI
2.	Harris KA and Reese DM: Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs. 61:2177–2192. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Chan JM, Gann PH and Giovannucci EL: Role of diet in prostate cancer development and progression. J Clin Oncol. 23:8152–8160. 2005. View Article : Google Scholar : PubMed/NCBI
4.	King IB, Kristal AR, Schaffer S, Thornquist M and Goodman GE: Serum trans-fatty acids are associated with risk of prostate cancer in beta-Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 14:988–992. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK and Bisoffi M: Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol. 35:537–546. 2009.PubMed/NCBI
6.	Baron A, Migita T, Tang D and Loda M: Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem. 91:47–53. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Di Nunzio M, van Deursen D, Verhoeven AJ and Bordoni A: n-3 and n-6 Polyunsaturated fatty acids suppress sterol regulatory element binding protein activity and increase flow of non-esterified cholesterol in HepG2 cells. Br J Nutr. 103:161–167. 2010.
8.	Worgall TS, Sturley SL, Seo T, Osborne TF and Deckelbaum RJ: Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein. J Biol Chem. 273:25537–25540. 1998. View Article : Google Scholar
9.	Xu J, Nakamura MT, Cho HP and Clarke SD: Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem. 274:23577–23583. 1999. View Article : Google Scholar
10.	Nakatani T, Kim HJ, Kaburagi Y, Yasuda K and Ezaki O: A low fish oil inhibits SREBP-1 proteolytic cascade, while a high-fish-oil feeding decreases SREBP-1 mRNA in mice liver: relationship to anti-obesity. J Lipid Res. 44:369–379. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS and Nelson JB: Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 47:102–110. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE and Kuhajda FP: Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 56:2745–2747. 1996.PubMed/NCBI
13.	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Neumann F: Pharmacology and clinical use of antiandrogens: a short review. Ir J Med Sci. 151:61–70. 1982. View Article : Google Scholar : PubMed/NCBI
15.	Gaillard-Moguilewsky M: Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy. Urology. 37:5–12. 1991. View Article : Google Scholar : PubMed/NCBI
16.	Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Cansino Alcaide JR, Vera San Martin R, Rodriguez de Bethencourt Codes F, Bouraoui Y, Rodriguez Berriguete G, Oueslati R, Perez-Utrilla M, De la Pena Barthel J, Paniagua Gomez-Alvarez R and Royuela Garcia M: Prostatic specific antigen (PS), pro-inflammatory cytokines, and prostatic pathology (benign prostatic hyperplasia and cancer). Relationship with malignancy. Arch Esp Urol. 62:359–366. 2009.(In Spanish).
19.	Bouraoui Y, Ricote M, Garcia-Tunon I, Rodriguez-Berriguete G, Touffehi M, Rais NB, Fraile B, Paniagua R, Oueslati R and Royuela M: Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer Detect Prev. 32:23–32. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD and Zhang J: Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res. 67:3646–3653. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z and Zhang J: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311–1318. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Shi CL, Yu CH, Zhang Y, Zhao D, Chang XH and Wang WH: Monocyte chemoattractant protein-1 modulates invasion and apoptosis of PC-3M prostate cancer cells via regulating expression of VEGF, MMP9 and caspase-3. Asian Pac J Cancer Prev. 12:555–559. 2011.PubMed/NCBI
23.	Hsieh TC and Chiao JW: Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist. Cancer Lett. 95:119–123. 1995. View Article : Google Scholar : PubMed/NCBI
24.	Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI
25.	Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 58:1008–1015. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Kim SW, Kim JS, Papadopoulos J, Choi HJ, He J, Maya M, Langley RR, Fan D, Fidler IJ and Kim SJ: Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol. 11:862–872. 2011.
27.	Kyprianou N: Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol. 12:299–303. 1994. View Article : Google Scholar : PubMed/NCBI
28.	Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS and Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55:4438–4445. 1995.PubMed/NCBI
29.	Thompson MR, Xu D and Williams BR: ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl). 87:1053–1060. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Chen BP, Liang G, Whelan J and Hai T: ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem. 3:15819–15826. 1994.PubMed/NCBI
31.	Huang X, Li X and Guo B: KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem. 283:29795–29801. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Terry PD, Rohan TE and Wolk A: Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr. 77:532–543. 2003.PubMed/NCBI
33.	Friedrichs W, Ruparel SB, Marciniak RA and DeGraffenried L: Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. Nutr Cancer. 63:771–777. 2011. View Article : Google Scholar : PubMed/NCBI
34.	De Stefani E, Deneo-Pellegrini H, Boffetta P, Ronco A and Mendilaharsu M: Alpha-linolenic acid and risk of prostate cancer: a case-control study in Uruguay. Cancer Epidemiol Biomarkers Prev. 9:335–338. 2000.
35.	Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC and Giovannucci EL: Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr. 80:204–216. 2004.PubMed/NCBI
36.	Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, et al: Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 101:519–532. 2009. View Article : Google Scholar : PubMed/NCBI
37.	Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S and Loda M: Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 1:707–715. 2003.PubMed/NCBI
38.	Gillies PJ, Bhatia SK, Belcher LA, Hannon DB, Thompson JT and Vanden Heuvel JP: Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil. J Lipid Res. 53:1679–1689. 2012. View Article : Google Scholar : PubMed/NCBI
39.	Pawlosky RJ, Hibbeln JR and Salem N Jr: Compartmental analyses of plasma n-3 essential fatty acids among male and female smokers and nonsmokers. J Lipid Res. 48:935–943. 2007. View Article : Google Scholar : PubMed/NCBI
40.	Harper CR, Edwards MJ, DeFilippis AP and Jacobson TA: Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. J Nutr. 136:83–87. 2006.PubMed/NCBI
41.	Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE and Vatten L: Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer. 71:545–551. 1997. View Article : Google Scholar : PubMed/NCBI
42.	Schonberg SA, Lundemo AG, Fladvad T, Holmgren K, Bremseth H, Nilsen A, Gederaas O, Tvedt KE, Egeberg KW and Krokan HE: Closely related colon cancer cell lines display different sensitivity to polyunsaturated fatty acids, accumulate different lipid classes and downregulate sterol regulatory element-binding protein 1. FEBS J. 273:2749–2765. 2006. View Article : Google Scholar
43.	Cavazos DA, Price RS, Apte SS and deGraffenried LA: Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF-κB. Prostate. 71:1420–1428. 2011.PubMed/NCBI